Sunday, September 29, 2019 12:04:35 PM
________________________________________________________________________________
Comments to put the shelf offering in perspective:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149743089
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149743702
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149748255
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149780479
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149784662
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149788415
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149801350
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150059795
General analysis of S-3 filings -
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149784281
Link to Annual Report:
https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/s114606_10k.htm
Link to all SEC filings:
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001314052&action=getcompany
Link to Pipeline graphic: https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/img001_v1.jpg
Mouse PET images: https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/img002_v1.jpg
PIPELINE
Evolution of the pipeline:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147064606
Results of 4/5/19 shareholder vote:
https://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/s117292_8k.htm
Shareholder rights plan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145724043
Company website - upcoming and past events:
https://www.anavex.com/investor-material/events/
Company Website - presentations on line:
https://www.anavex.com/investor-material/
Transcript of 12/12/18 Conference call:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145435190
Access to 12/18 Conference call:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145347046
** note that current and past conference calls and transcripts should be added here
Quick link to SEC filings:
https://fintel.io/filings/us/avxl
Link to SEC filings on EDGAR:
https://www.sec.gov/cgi-bin/browse-edgar?CIK=avxl&owner=exclude&action=getcompany
____________________________________________________________________________________
SHAREHOLDER'S MEETING NOTES:
Discussion of shareholder's meeting 04/05/19 begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148045215
Thanks to our MB, on the scene reporters...
brichnyc, bourbon, and Jonjones325
From bourbon_on_my_cornflakes:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148047383
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148050828
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148058557
From Jonjones325:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148057082
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148057307
From brichnyc:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148084098
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148086244
2018 Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467
__________________________________________________________________________________________________
UPCOMING PRESENTATIONS, OTHER POSSIBLE EVENTS:
Oct 11 : Australasian Consortium Of Centres For Clinical Cognitive Research (AC4R) Annual Scientific Meeting - Sydney, AU
“The sigma 1 receptor– blocking protein misfolding” - Dr. Missling
https://www.ac4r.com.au/wp-content/uploads/2019/08/AC4R-ASM-Conference-Agenda-2019-1.pdf
Also speaking at this one-day event will be A/Prof Michael Woodward of Austin Health, Prof Simon Lewis of the University of Sydney, and Prof Phillip Morris of the Gold Coast Memory Disorders Clinic — there's no reason to believe their appearances are related, but each of them run AD clinical trial sites for 2-73 at their respective institutions.(copy snitched from TTTav66)
Coomment on this from traderherpete:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150868995
see Also:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151080828
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150867161
Dec 5 : 3rd Microbiome Movement – Gut-Brain Axis Summit - Boston, MA
"Sharing Clinical Data that Identifies Gut Microbiota Biomarkers Associated with Improved Clinical Response in Alzheimer’s Disease Patients Treated with ANAVEX®2-73" - Dr. Missling
https://microbiome-gba.com/seminar/sharing-clinical-data-that-identifies-gut-microbiota-biomarkers-associated-with-improved-clinical-response-in-alzheimers-disease-patients-treated-with-anavex2-73/
16th international conference on Dementia and Alzheimer Disease
February 10-11, 2020 Sydney, Australia (from georgejjl)
https://dementia.annualcongress.com/events-list/parkinson-s-disease
Possible Catalysts
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145908635
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148107153
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149157245
We are still awaiting Dr Kaufmann's presentation on gut microbiome data. (from kevli33)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148871706
_________________________________________________________________________________
RECENT HAMPEL COMMENTS AND PAPERS:
Hampel: “What Electrophysiology Tells Us About Alzheimer’s Disease: A Window into the Synchronization and Connectivity of Brain Neurons - ScienceDirect”(from Investor2014)
https://www.sciencedirect.com/science/article/abs/pii/S019745801930329
Hampel: Revolution of Alzheimer Precision Neurology,Passageway of Systems Biology and Neurophysiology(from kevli33 )
https://content.iospress.com/download/journal-of-alzheimers-disease/jad179932?id=journal-of-alzheimers-disease%2Fjad179932
HH Tweet on AI:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150177121
Hampel on our "small" P2a:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149548350
Time for the systems-level integration of aging:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150247109
See also Anavex Partnerships under Precision Medicine Initiative
_________________________________________________________________________________
PAST PRESENTATIONS:
Anavex presentations -
https://www.anavex.com/presentations/
Including these for 2019
6th Annual European Rett Syndrome Conference September 2019 (Finland)
https://www.anavex.com/wp-content/uploads/2019/09/ANAVEX2-73-RS-001-Finland-Conference-Sept-2019-Final.pdf
Janney presentation September 2019 (audio)
https://www.anavex.com/wp-content/uploads/2019/09/Janney-Audio-Presentation-Sept-2019.mp3
Corporate presentation March 2019
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-Presentation-March-2019-1.pdf
ASENT 21th Annual Meeting Conference March 2019
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-ASENT-March-2019.pdf
upcoming medical journal
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150808695
Presentation links from georgejjl:
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-AAIC-2018-DT-Presentation.pdf
https://www.anavex.com/wp-content/uploads/2018/05/Anavex-Presentation-May-2018-1.pdf
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-ASENT-March-2019.pdf
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-Presentation-March-2019-1.pdf
https://www.anavex.com/wp-content/uploads/2019/07/Anavex-Microbiota-Presentation-AAIC-July-2019-1.pdf
Feb. 11-12 : BIO CEO & Investor Conference
Presentation
https://www.veracast.com/webcasts/bio/ceoinvestor2019/78204240532.cfm?0.22201266802
Slides only
https://www.anavex.com/wp-content/uploads/2019/02/Anavex-BIO-CEO-Feb-2019-1.pdf
Cantor Fitzgerald Presentation from Cantor Fitzgerald Global Healthcare Conference October 3, 2018 2:50 p.m.
http://wsw.com/webcast/cantor7/avxl/
Comment on the above from dia76ca "At Cantor Dr. Missing said that the Rett trial would "clear VERY SOON"(At the 27:30 minute mark). We would do well to remember some of the other things he said.(e.g. Cash on hand for 2 years...21:21 minute mark ; Anavex 3-71 in clinic in 2019...29:34 minute mark ; Parkinson read-out in 2019...30:40 minute mark."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144349470
Additional audio presentations on the company web site see links at top of post.
_________________________________________________________________________________________________
VIDEO PRESENTATIONS
Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781
History of rettsyndrome.org featuring Christopher Missling:
Missling interview:
Walter E. Kaufmann
Until recently, he was the Director of the Center for Translational Research at the Greenwood Genetic Center, where he also held the Ravenel Boykin Curry Chair in Genetic Therapeutics. Now he is the Anavex CMO. (originally posted by kevli33)
Dr. Tangui Maurice on the Sigma 1 - 2015 video:(from kevli33)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208
SAB member Jacquelin French, videos discussing Seizures and Epilepsy: (from kevli33)
Videos from UC and Rob Knight (not Anavex specific, but cutting edge science.)
Microbiomes and aging:
Microbiome mind and brain interaction:
https://www.youtube.com/watch?v=2iKHMyWzclM&t=134s
All of Rob Knight's videos are interesting:
https://www.youtube.com/results?search_query=rob+knight
Dementia risk and blood pressure from kevli33:
Macfarlane on medication in dementia:
Additional video presentations on the company web site see links at top of post.
_________________________________________________________________________________________________
SLIDE SHOWS AND POSTERS:
AAIC Gut Brain slide show
https://www.anavex.com/wp-content/uploads/2019/07/Anavex-Microbiota-Presentation-AAIC-July-2019-1.pdf
See the GUT BRAIN link at the bottom of this post for comments and discussion.
October Corporate Presentation used at the Cantor Fitzgerald Conference
https://www.anavex.com/wp-content/uploads/2018/10/Anavex-Presentation-Oct-2018.pdf
Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims
Anavex 2-73 as a potential treatment for autism spectrum disorders 2016
https://anavex.com/wp-content/uploads/2016-06-06_Poster_AV2-73_Autism_FXS_Conference_June_2016.pdf
Kaufmann presentation 3/27/19
American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-ASENT-March-2019.pdf
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-Presentation-March-2019-1.pdf
Titration could increase the response and efficacy of Anavex 2-73.
A plasma concentration of greater than 4 ng/ml would increase postive responses and efficacy to Anavex 2-73 (from georgejjl)
Slide 10
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147511076
From Slide 27:
What is Actigraphy Monitoring? Mentioned in 3/19 Missling presentation. (from nidan7500)
https://www.verywellhealth.com/what-is-actigraphy-3015130
https://www.actigraphcorp.com/
CTAD 2018 slides - see the following archive
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146087872
____________________________________________________________________________________________
POSSIBLE SIGNS OF MOVE TOWARD COMMERCIALIZATION:
Does 2-73 have a name?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146539861
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540287
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540557
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146545746
Info on why Anavex needed to spend $1 million on product development in 2018. (from ohsaycanyousee82)
http://www.pharmtech.com/api-sourcing
Discussion of above follows this post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146733092
September 25-27 AAIC down under
https://www.ac4r.com.au/
https://alz.org/sydney/downloads/AAIC%20Satellite%20Symposium%20Sydney%20Agenda_8.7_final.pdf
Xena opinion: part of Aussie systemic preparation for P4 trials.
Supporting post
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150854241&txt2find=rowe
__________________________________________________________________________________________________
GENERAL TRIAL DISCUSSION AND COMMENTS ON TRIAL PROCEDURE:
These discussions are moved to the "OTHER COUNTRIES - General Coments" post, see the links at the end. For more on Cognition, Neuronetrix, and the Consortium see the Anavex Parnters link at the end.
__________________________________________________________________________________________________
MISCELLANEOUS DISCUSSION:
Anavex extended trials defining a new sort of success:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150370866
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150373170
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150380618
The industry of aging
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150881079
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150881395
Systems theory and systems biology paradigms bio
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149449161
Derek Lowe's commentary on drug discovery and the pharma industry.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151382722
Neurodevelopment in children:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143439222
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151301338
Protein degradation disease treatments:
https://www.investors.com/news/technology/protein-degradation-eyed-pharmaceutical-companies-drug-development/
AI estimates brain age:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147255249
Orphan Disease Designation in Rett and Infantile Spasm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540508
The U.S. has a "national mental health epidemic. The damage is on the scale of the global financial crisis." (from Lima4918)
https://www.bloomberg.com/news/articles/2019-06-20/latest-suicide-data-show-the-depth-of-u-s-mental-health-crisis?srnd=premium
Rising to the Challenge: Developing New Medicines for Rare Disease (from kevli33)
https://checkrare.com/rising-to-the-challenge-developing-new-medicines-for-rare-disease/
Expansion of rare disease diagnostic codes (from nidan7500)
https://dravetsyndromenews.com/2019/02/04/icd-10-codes-really-important-to-rare-disease-patients-soon-up-for-fresh-consideration/
Missling has a strategy - comments from posters on that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144350599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164402
Personal comments from falconer66a on the failure of traditional western medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144979916
How the U.S. is failing its people in healthcare:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145076878
Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently
Sokol with a 2016 perspective on potential Alzheimer's treatments:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144809093
Falconer taking the temperature of the medical research community:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148589256
2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307
Anavex 2-73 might show better results with younger patients than older patients.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148058285
Comment on industry trends (link from PennyDouble)
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/us-and-global-life-sciences-industry-trends-outlook.html
2015 new discovery about the brain and the immune system:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148062119
“Enabling precision medicine with integrated genomic and clinical data” posted by Harald Hampel and kevli33
https://twitter.com/harald_hampel/status/1114590967531753472?s=21
https://azure.microsoft.com/en-us/blog/enabling-precision-medicine-with-integrated-genomic-and-clinical-data/
Old brains and neurogenesis (from powerwalker).
https://www.statnews.com/2019/03/25/old-brains-make-new-neurons-possibly-protecting-against-alzheimers/
Top 20 CNS drug companies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147869585
Anavex is not just a drug company - opinion from Lima4918
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147759921
A new urgency for Expanded Access:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147906853
An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176
Sokol on Anavex's international strategies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144504285
Link to PeterKarol's blog:
https://piotrpeterblog.com/
Scientists rise up against statistical significance (from Biostockclub)
https://www.nature.com/articles/d41586-019-00857-9
Life expectancy in the US still continues to go down, 2018 graphic:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147424525
Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988
_________________________________________________________________________________________________
GENERAL CNS Diagnostics and Biomarkers:
Biomarkers and decision making
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150383196
The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149674738
On Biomarkers and Surrogate Endpoints. A read forward into the discussion is suggested for additional information on sleep and Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145241236
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145245388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145245674
(several posts follow the last link)
Cognision and ERP/EEG tracking in trials - is this why trials are adding sites slowly?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148909354
Possible approval based on sleep, with ERP/EEG taken as suporting biomarker evidence
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148919365
More biomarker info under individual diseases- see link at the end of this post
______________________________________________________________________________________________
TRIAL PROCEDURE:
Reasons why it's good to be running trials in Australia...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147033379
Data from another trial can be used to support an approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148906992
Japan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770129
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770231
Multi-regional clinical trials and global drug development - 2016 changes in trial technique:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099281
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099929
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149100322
Procedure and implications of post trial access to drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149179546
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149180303
U.S. FDA: 09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418809
AUSTRALIA'S TGA: 09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418733
OTHER COUNTRIES-General Comments: 08/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150393295
_____________________________________________________________________________________________
LINKS TO OTHER SECTIONS:
SPECIFIC INDICATIONS09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418934
MOA and MEDICAL SCIENCE DISCUSSION 09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418911
IP Protection:09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418888
GUT and BRAIN - barrier and permeability 09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418789
PRESS AND THIRD PARTY 09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418761
BIG PHARMA and Potential Partners 9/26/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151368809
AVXL -The Stock and the Market 9/26/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151368338
3-71 Discussion 09/29/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418818
SLEEP 08/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150393238
Anavex Partners 08/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150393213
Elder Care Crisis:07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887464
The People of Anavex 07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887343
Genetic issues- sex and more 07/12/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887394
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM